Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study
Chang Zhi-wei, Liang Wei, Jun Liu, Xiumei Ma et al.
Citations
7 citations
Journal
The Oncologist
Topics
Esophageal Cancer Research and Treatment
Field-Weighted Citation Impact (FWCI)
4.01
article
Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study
Chang Zhi-wei, Liang Wei, Jun Liu, Xiumei Ma, Guifang Zhang, Jing Huang, Ping Lu, Yongjing Tian, Jin Xia, Heng Cao, Yonggui Hong
article en
7 citations
Abstract
No abstract available for this paper.
Publication Tag
The OncologistVol. 30(3)
Institutions
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Renji Hospital (CN), Shanghai Chest Hospital (CN), First Affiliated Hospital of Xinxiang Medical University (CN), Nanyang Institute of Technology (CN), National Clinical Research (US), Xinxiang Central Hospital (CN), First Affiliated Hospital of Zhengzhou University (CN), Cixian People's Hospital (CN), Anyang Tumor Hospital (CN), Henan Medical University (CN)